<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Vet Intern Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Vet. Intern. Med</journal-id>
      <journal-id journal-id-type="doi">10.1111/(ISSN)1939-1676</journal-id>
      <journal-id journal-id-type="publisher-id">JVIM</journal-id>
      <journal-title-group>
        <journal-title>Journal of Veterinary Internal Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0891-6640</issn>
      <issn pub-type="epub">1939-1676</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26455583</article-id>
      <article-id pub-id-type="pmc">4895669</article-id>
      <article-id pub-id-type="doi">10.1111/jvim.13637</article-id>
      <article-id pub-id-type="publisher-id">JVIM13637</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Case Report</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>SMALL ANIMAL</subject>
          <subj-group subj-group-type="heading">
            <subject>Case Reports</subject>
            <subj-group subj-group-type="heading">
              <subject>Nephrology/Urology</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Dissolution of Urinary Bladder Clots in a Dog with Alteplase</article-title>
        <alt-title alt-title-type="left-running-head">Pineda et&#xA0;al</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="jvim13637-cr-0001" contrib-type="author" corresp="yes">
          <name>
            <surname>Pineda</surname>
            <given-names>C.</given-names>
          </name>
          <xref ref-type="aff" rid="jvim13637-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jvim13637-cr-0002" contrib-type="author">
          <name>
            <surname>Guisado</surname>
            <given-names>A.</given-names>
          </name>
          <xref ref-type="aff" rid="jvim13637-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jvim13637-cr-0003" contrib-type="author">
          <name>
            <surname>Aguilera&#x2010;Tejero</surname>
            <given-names>E.</given-names>
          </name>
          <xref ref-type="aff" rid="jvim13637-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jvim13637-cr-0004" contrib-type="author">
          <name>
            <surname>Lopez</surname>
            <given-names>I.</given-names>
          </name>
          <xref ref-type="aff" rid="jvim13637-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="jvim13637-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Department of Medicina y Cirugia Animal</named-content>
        <institution>Universidad de Cordoba</institution>
        <named-content content-type="city">Cordoba</named-content>
        <country country="ES">Spain</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>Corresponding author: C. Pineda, Department of Medicina y Cirugia Animal, Campus Universitario Rabanales, Ctra. Madrid&#x2010;Cadiz km 396. 14014 Cordoba, SPAIN; e&#x2010;mail: <email>v32pimac@uco.es</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2015</year>
      </pub-date>
      <volume>29</volume>
      <issue>6</issue>
      <issue-id pub-id-type="doi">10.1111/jvim.2015.29.issue-6</issue-id>
      <fpage>1627</fpage>
      <lpage>1628</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>5</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>30</day>
          <month>6</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>9</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2015 American College of Veterinary Internal Medicine <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Copyright &#xA9; 2015 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.</copyright-statement>
        <license license-type="creativeCommonsBy-nc">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x2010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JVIM-29-1627.pdf"/>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="jvim13637-kwd-0001">Canine</kwd>
        <kwd id="jvim13637-kwd-0002">Idiopathic renal hematuria</kwd>
        <kwd id="jvim13637-kwd-0003">Intravesical clot</kwd>
        <kwd id="jvim13637-kwd-0004">Recombinant tissue plasminogen activator</kwd>
      </kwd-group>
      <counts>
        <page-count count="2"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>jvim13637</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>November/December 2015</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.9 mode:remove_FC converted:06.05.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <fn-group id="jvim13637-ntgp-0101">
        <fn id="jvim13637-note-0101">
          <p>The work was done at the Department of Medicina y Cirugia
Animal &#x2013; Small Animal Veterinary Teaching Hospital, University of Cordoba, Cordoba, Spain.</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body>
    <def-list list-content="abbreviations" id="jvim13637-dl-0001">
      <title>Abbreviations</title>
      <def-item>
        <term>aPTT</term>
        <def>
          <p>activated partial thromboplastin time</p>
        </def>
      </def-item>
      <def-item>
        <term>CBC</term>
        <def>
          <p>complete blood count</p>
        </def>
      </def-item>
      <def-item>
        <term>FDP</term>
        <def>
          <p>fibrinogen&#x2010;degradation product</p>
        </def>
      </def-item>
      <def-item>
        <term>MCHC</term>
        <def>
          <p>mean corpuscular hemoglobin concentration</p>
        </def>
      </def-item>
      <def-item>
        <term>MCV</term>
        <def>
          <p>mean corpuscular volume</p>
        </def>
      </def-item>
      <def-item>
        <term>PCV</term>
        <def>
          <p>packed cell volume</p>
        </def>
      </def-item>
      <def-item>
        <term>PT</term>
        <def>
          <p>prothrombin time</p>
        </def>
      </def-item>
      <def-item>
        <term>RBC</term>
        <def>
          <p>red blood cell</p>
        </def>
      </def-item>
      <def-item>
        <term>RRI</term>
        <def>
          <p>renal resistive index</p>
        </def>
      </def-item>
      <def-item>
        <term>r&#x2010;TPA</term>
        <def>
          <p>recombinant tissue plasminogen activator</p>
        </def>
      </def-item>
      <def-item>
        <term>TT</term>
        <def>
          <p>thrombin time</p>
        </def>
      </def-item>
    </def-list>
    <p>A 3&#x2010;year&#x2010;old male intact Spanish Water Dog was referred to the Small Animal Veterinary Teaching Hospital of the University of Cordoba for investigation of persistent hematuria and dysuria. Intermitent hematuria had been present as the dog was 4&#xA0;months old. As the dog had been suffering this problem for several years, before presentation, it had received a variety of treatments including vitamin K, anti&#x2010;inflammatory drugs, and antibiotics.</p>
    <p>On presentation the dog was quiet, alert, and responsive. The only relevant finding on physical examination was slightly pale mucous membranes. Complete blood cell count (CBC) was consistent with moderate microcytic and hypochromic semiregenerative anemia (PCV 34%; RI, 37.0&#x2013;54.0%; MCV 55.5&#xA0;fL; RI, 62.0&#x2013;74.0&#xA0;fL; MCHC 25.4&#xA0;g/dL; RI, 32.0&#x2013;36.0&#xA0;g/dL; reticulocytes 0.5%). Abnormalities in blood biochemistry included slight hypoalbuminemia (2.1&#xA0;g/dL; RI, 2.5&#x2013;3.5&#xA0;g/dL), slight hyperbilirubinemia (0.6&#xA0;mg/dL; RI, 0.1&#x2013;0.3&#xA0;mg/dL), and severe iron deficiency (16.7&#xA0;&#x3BC;g/dL; RI, 84.0&#x2013;233.0&#xA0;&#x3BC;g/dL). Results of the coagulation tests were within the reference ranges (aPTT 16.8 secs; RI, &lt;25&#xA0;secs; TT &lt;15.8 secs; RI, &lt;15.8 secs; PT 7.2 secs; RI, 5.9&#x2013;9.8 secs; FDP &lt;0.1; RI &lt;0.1). Urine was obtained via cystocentesis, and urinalysis revealed a pH = 6.5, specific gravity = 1026, occult blood (3+), bilirubinuria (3+), proteinuria (4+), and slight leucocituria (+), as determined by urine dipstick tests. Microscopic examination of urine sediment revealed red blood cells (RBC) too numerous to count (&gt;50 RBC/high power field). The urine culture was negative.</p>
    <p>No abnormalities were detected on 3&#x2010;view abdominal radiographs. Excretory urography did not show morphological or functional abnormalities.</p>
    <p>Abdominal ultrasound revealed a large clot in the lumen of the urinary bladder (Fig&#xA0;<xref rid="jvim13637-fig-0001" ref-type="fig">1</xref>A). No structural renal abnormalities were observed, although the Doppler study revealed bilateral renal hypoperfusion and increased renal resistive index (RRI) in both kidneys (RRI &gt;0.70).</p>
    <fig fig-type="Figure" xml:lang="en" id="jvim13637-fig-0001" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Ultrasound images of the urinary bladder, before (<bold>A</bold>) and after (<bold>B</bold>) intravesical treatment with alteplase. Note the presence of a large intravesical clot before treatment and its dissolution after instillation of alteplase.</p>
      </caption>
      <graphic id="nlm-graphic-1" xlink:href="JVIM-29-1627-g001"/>
    </fig>
    <p>Based on these data, a tentative diagnosis of idiopathic renal hematuria was made. Dysuria was considered to be secondary to impairment in urinary tract outflow caused by the large clot detected inside the bladder. Because of financial constraints, the owner declined further diagnostics. As surgical treatment for renal hematuria was not a viable option, a conservative medical approach aimed to reduce bleeding with oral aminocaproic acid<xref ref-type="fn" rid="jvim13637-note-0001">1</xref> (50&#xA0;mg/kg q8&#xA0;hours) and to treat anemia with an iron and folic acid supplement<xref ref-type="fn" rid="jvim13637-note-0002">2</xref> (300&#xA0;mg iron gluconate, 1&#xA0;mg folic acid q12&#xA0;hours) was started.</p>
    <p>To treat dysuria, which was the problem that was causing more discomfort to the dog, a decision was made to attempt dissolution of the urinary bladder clot using alteplase,<xref ref-type="fn" rid="jvim13637-note-0003">3</xref> a recombinant tissue plasminogen activator (r&#x2010;TPA), following a method previously described in human neonatology.<xref rid="jvim13637-bib-0001" ref-type="ref">1</xref> Urethral catheterization was performed with an 8 Fr Foley urinary catheter.<xref ref-type="fn" rid="jvim13637-note-0004">4</xref> One milligram of alteplase<xref ref-type="fn" rid="jvim13637-note-0003">3</xref> was diluted to 10&#xA0;mL with saline solution, and 5&#xA0;mL of this solution (0.5&#xA0;mg) were instilled into the urinary bladder through the Foley catheter. The catheter was clamped for 1&#xA0;hour, after that the bladder was flushed with 10&#xA0;mL of saline solution. Eight hours later, the procedure was repeated with the remaining 5&#xA0;mL of alteplase solution. After instillation of the remaining dose of TPA, a complete dissolution of the intravesical clot was observed during the ultrasound follow up (Fig&#xA0;<xref rid="jvim13637-fig-0001" ref-type="fig">1</xref>B).</p>
    <p>Subsequently, local washes were repeated when presence of clots caused urinary tract obstruction and retention. A total of 6 intravesical TPA instillations were performed with an approximate interval of 1&#xA0;month between each treatment. Although further sporadic episodes of hematuria have occurred, they have not been accompanied by large intravesical clots or difficulty urinating.</p>
    <p>In the dog of this report, intravesical clots were causing urinary obstruction and thus clot removal was an important therapeutic goal. Thrombolytic treatment provides a less invasive option than surgery for the resolution of urinary bladder clots. In humans, the use of several thrombolytics such as streptokinase,<xref rid="jvim13637-bib-0002" ref-type="ref">2</xref> urokinase,<xref rid="jvim13637-bib-0003" ref-type="ref">3</xref> alteplase,<xref rid="jvim13637-bib-0001" ref-type="ref">1</xref> and chymotrypsin combined with sodium bicarbonate irrigation technique has been described.<xref rid="jvim13637-bib-0004" ref-type="ref">4</xref>
</p>
    <p>We decided to use alteplase for the dissolution of the urinary bladder clot based on a previous report in a human neonate in which efficacy and safety of this thrombolytic agent was demonstrated.<xref rid="jvim13637-bib-0001" ref-type="ref">1</xref> Alteplase (recombinant type plasminogen activator [r&#x2010;TPA]) is a serine protease produced mainly by endothelial cells that is involved in the fibrinolysis of blood clots by converting inactive endogenous plasminogen to plasmin.<xref rid="jvim13637-bib-0005" ref-type="ref">5</xref> Alteplase is more fibrin&#x2010;specific than streptokinase or urokinase, resulting in less depletion of plasma fibrinogen and in fewer degradation products.<xref rid="jvim13637-bib-0005" ref-type="ref">5</xref> Because of the lack of established dosing guidelines for intravesical alteplase in small animals, we used the dose previously reported in neonatal human medicine.<xref rid="jvim13637-bib-0001" ref-type="ref">1</xref> Although alteplase is considered a safe thrombolytic agent adverse effects can occur, of which hemorrhage is the most important.<xref rid="jvim13637-bib-0001" ref-type="ref">1</xref> In agreement with the previous human report,<xref rid="jvim13637-bib-0001" ref-type="ref">1</xref> treatment with TPA was well tolerated, in our case no bleeding signs and no changes in the coagulation profile were observed when alteplase was administered locally (intravesical).</p>
    <p>Our case shows that the intravesical administration of alteplase is a viable option for the resolution of urinary bladder clots in dogs. This medical treatment has obvious advantages when compared with surgical removal, including being less invasive, cheaper, and the possibility of performing as many treatments as necessary every time that intravesical clot formation becomes a problem. Nevertheless, further experience with the use of this drug is needed to establish the exact dose and duration of the treatment in small animals.</p>
  </body>
  <back>
    <ack id="jvim13637-sec-0002">
      <title>Acknowledgments</title>
      <p>
<italic>Conflict of Interest Declaration:</italic> Authors disclose no conflict of interest.</p>
      <p>
<italic>Off&#x2010;label Antimicrobial Declaration:</italic> Authors declare no off&#x2010;label use of antimicrobials.</p>
    </ack>
    <fn-group id="jvim13637-ntgp-0001">
      <title>Footnotes</title>
      <fn id="jvim13637-note-0001">
        <label>1</label>
        <p>Aminocaproic acid (Caproamin Fides, 4&#xA0;g/10&#xA0;mL), Fides&#x2010;Rottapharm S.A., Valencia, Spain.</p>
      </fn>
      <fn id="jvim13637-note-0002">
        <label>2</label>
        <p>Iron and folic acid supplement (Normovite antianemico, 300/1&#xA0;mg), Normon S.A., Madrid, Spain.</p>
      </fn>
      <fn id="jvim13637-note-0003">
        <label>3</label>
        <p>Alteplase (Actilyse, 1&#xA0;mg), Boehringer Ingelheim S.A., Barcelona, Spain.</p>
      </fn>
      <fn id="jvim13637-note-0004">
        <label>4</label>
        <p>Foley urinary catheter 8 Fr, MILA International Inc., Kentucky, USA.</p>
      </fn>
    </fn-group>
    <ref-list content-type="cited-references" id="jvim13637-bibl-0001">
      <title>References</title>
      <ref id="jvim13637-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="jvim13637-cit-0001">
<string-name>
<surname>Olarte</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Glover</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Totapally</surname>
<given-names>BR</given-names>
</string-name>. <article-title>The use of alteplase for the resolution of an intravesical clot in a neonate receiving extracorporeal membrane oxygenation</article-title>. <source>ASAIO J</source>
<year>2001</year>;<volume>47</volume>:<fpage>565</fpage>&#x2013;<lpage>568</lpage>.<pub-id pub-id-type="pmid">11575839</pub-id></mixed-citation>
      </ref>
      <ref id="jvim13637-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="jvim13637-cit-0002">
<string-name>
<surname>Korkmaz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sahin</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Islim</surname>
<given-names>F</given-names>
</string-name>, et&#xA0;al. <article-title>A new treatment for clot retention: intravesical streptokinase instillation</article-title>. <source>J Urol</source>
<year>1996</year>;<volume>156</volume>:<fpage>201</fpage>.<pub-id pub-id-type="pmid">8648803</pub-id></mixed-citation>
      </ref>
      <ref id="jvim13637-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="jvim13637-cit-0003">
<string-name>
<surname>LaFave</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Decter</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Intravesical urokinase for the management of clot retention in boys</article-title>. <source>J Urol</source>
<year>1993</year>;<volume>150</volume>:<fpage>1467</fpage>&#x2013;<lpage>1468</lpage>.<pub-id pub-id-type="pmid">8411427</pub-id></mixed-citation>
      </ref>
      <ref id="jvim13637-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="jvim13637-cit-0004">
<string-name>
<surname>Bo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yangvang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jiayuan</surname>
<given-names>L</given-names>
</string-name>, et&#xA0;al. <article-title>Evaluation of bladder clots using a nonsurgical treatment</article-title>. <source>Urology</source>
<year>2014</year>;<volume>83</volume>:<fpage>498</fpage>&#x2013;<lpage>499</lpage>.<pub-id pub-id-type="pmid">24315307</pub-id></mixed-citation>
      </ref>
      <ref id="jvim13637-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="jvim13637-cit-0005">
<string-name>
<surname>Gillis</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Wagstaff</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Goa</surname>
<given-names>KL</given-names>
</string-name>. <article-title>Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction</article-title>. <source>Drugs</source>
<year>1995</year>;<volume>50</volume>:<fpage>102</fpage>&#x2013;<lpage>136</lpage>.<pub-id pub-id-type="pmid">7588083</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
